MET Human

The Met proto-oncogene, also known as the hepatocyte growth factor receptor, is a member of the receptor tyrosine kinase family. It plays a crucial role in various cellular processes, including growth, survival, and migration. The human recombinant form of this protein is of significant interest in both research and therapeutic contexts due to its involvement in cancer and other diseases.

The Met proto-oncogene encodes a receptor tyrosine kinase that binds to its ligand, hepatocyte growth factor (HGF). This interaction induces dimerization and activation of the receptor, which subsequently triggers a cascade of downstream signaling pathways. These pathways are involved in cellular processes such as proliferation, differentiation, and motility .

The Met receptor is a heterodimer composed of an alpha and a beta subunit linked by disulfide bonds. The alpha subunit is extracellular, while the beta subunit spans the membrane and contains the intracellular tyrosine kinase domain .

Alterations in the Met proto-oncogene, such as gene amplification, mutations, and overexpression, have been implicated in various cancers, including renal cell carcinoma, hepatocellular carcinoma, and head and neck cancers . These alterations can lead to constitutive activation of the Met receptor, driving tumor growth, invasion, and metastasis .

The human recombinant Met proto-oncogene is typically produced using recombinant DNA technology. This involves cloning the Met gene into an expression vector, which is then introduced into a suitable host cell line, such as Escherichia coli or mammalian cells. The host cells are cultured under specific conditions to express the recombinant protein, which is subsequently purified using techniques such as affinity chromatography .

The production of recombinant Met proto-oncogene involves several steps, including gene cloning, expression, and purification. The gene is first cloned into an expression vector, which is then introduced into host cells. The cells are cultured under optimal conditions to ensure high-level expression of the recombinant protein. The protein is then purified using various chromatographic techniques to achieve the desired purity and activity .

Industrial production of recombinant Met proto-oncogene typically involves large-scale fermentation processes. Host cells expressing the recombinant protein are cultured in bioreactors under controlled conditions to maximize yield. The protein is then harvested and purified using scalable purification methods, such as affinity and ion-exchange chromatography .